Retail Revenue: $1.4 billion for Q3 2024. Adjusted EBITDA: $472 million for Q3 2024. Interactive Adjusted Revenues: $141 million for Q3 2024. Interactive Adjusted EBITDA: Loss...
Completion of enrollment in the European Phase 3 clinical trial ARES designed to evaluate efficacy and safety of MaaT013 in the treatment of acute Graft-versus-Host Disease;...
Nanobiotix S.A. RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3...
WYOMISSING, Pa., August 08, 2024–(BUSINESS WIRE)–PENN Entertainment, Inc. (“PENN” or the “Company”) (Nasdaq: PENN) today reported financial results for the three and six months ended June...